drugset

drugset / Trial / NCT02591095

A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer

NCT02591095 ↗

Phase 2 Completed 47 enrolled Centre Francois Baclesse ARCAGY/ GINECO GROUP · collab French Cancer Research Hospital Program · collab

NaSingle-groupOpen-labelTreatment

Summary

ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.

Timeline

Start: 2016-01
Primary completion: 2017-04
Completion: 2019-03

Publications

Joly F, Fabbro M, Follana P, Lequesne J, Medioni J, Lesoin A, Frenel JS, Abadie-Lacourtoisie S, Floquet A, Gladieff L, You B, Gavoille C, Kalbacher E, Briand M, Brachet PE, Giffard F, Weiswald LB, Just PA, Blanc-Fournier C, Leconte A, Clarisse B, Leary A, Poulain L. A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study. Gynecol Oncol. 2022 Apr;165(1):30-39. doi: 10.1016/j.ygyno.2022.01.021. Epub 2022 Feb 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Navitoclax	Small molecule	250 mg	Oral

Indications

No indication recorded.